Moderna Inc. and the future of vaccine technologies : management and protection of intellectual property /

At the beginning of the COVID-19 pandemic, Moderna Inc. jumped into the pharmaceutical race for a vaccine. Moderna Inc., a biotech pharmaceutical company founded in 2010 in Cambridge, Massachusetts, focuses on research and manufacturing vaccines using messenger RNA (mRNA) technology. As the pandemic...

Full description

Bibliographic Details
Main Author:	Trinh, Alan (Author)
Format:	eBook
Language:	English
Published:	London : SAGE Publications: SAGE Business Cases Originals, 2022.
Series:	SAGE business cases.
Subjects:	Intellectual property > Case studies. Vaccines > Case studies. Propriété intellectuelle > Études de cas. Vaccins > Études de cas. Intellectual property. Vaccines. Electronic books. Case studies.
Online Access:	Connect to the full text of this electronic book

Description
Summary:	At the beginning of the COVID-19 pandemic, Moderna Inc. jumped into the pharmaceutical race for a vaccine. Moderna Inc., a biotech pharmaceutical company founded in 2010 in Cambridge, Massachusetts, focuses on research and manufacturing vaccines using messenger RNA (mRNA) technology. As the pandemic continues, Moderna faces issues regarding its intellectual property and patents. Moderna must find strategies to manage and protect their intellectual properties in a focused niche of mRNA vaccines and therapeutics while balancing their ethical obligation to help as many people as possible as quickly as possible. Students are invited to think through various tactics that Moderna Inc. can use to manage and protect its intellectual property and determine an optimal strategy for the company post-pandemic.
Physical Description:	1 online resource.
Bibliography:	Includes bibliographical references and index.
ISBN:	9781529793208 1529793203